abbvie news - Search News

AbbVie, schizophrenia

MarketWatch on MSN · 2d

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

BioPharma Dive · 3d

On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Business Insider · 3d

AbbVie under pressure as schizophrenia drug fails two trials

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two

GlobalData on MSN · 2d

AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials

The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS.

BioPharma Dive · 3d

AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two Phase 2 trials.

AbbVie’s stumble, Amgen’s tumble and more election fallout

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

2d

Buy, Sell, Or Hold AbbVie Stock?

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

2h

2 Dividend Stocks to Buy Hand Over Fist in November

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

2d

AbbVie Stock Slides on Schizophrenia Drug Study Failure

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

3don MSN

AbbVie's closely watched schizophrenia drug fails two studies, shares slide

By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...

Despite setback, AbbVie’s big bet on neuroscience has yet to play out

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

14h

Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

3d

AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

5hon MSN

Final Trades: Bitcoin, Abbvie and Baker Hughes

Pomp Investments investor Anthony Pompliano discusses the likelihood of a Bitcoin boom on 'The Claman Countdown.' The ...

3d

Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results